COPD

Dupilumab demonstrates significant improvements in patients with COPD, type 2 inflammation by reducing exacerbations, improving lung function and quality of life, and alleviating respiratory symptoms.

An analysis of the COPDGene Study presented at ATS 2023 suggests presence of mucus plugs in medium- to large-sized airways were associated with an increased risk of mortality in adjusted models.

At West Penn Hospital, the harmonica program, currently in the pilot phase, aims to demonstrate its benefits in improving respiratory symptoms, reducing exacerbations, and enhancing patients' quality of life.

"Playing the harmonica has a therapeutic effect because of the pursed lip breathing technique it requires," Dr. Becky Jordan says in an interview.

Insomnia shows associations with higher rates of outpatient visits, hospitalizations, and fills for medications, longer hospital length of stay, and higher hospitalization costs.

New meta-analysis show patient demographics—as well as their pre-existing comorbidities and COVID-19 vaccination status—may significantly define their risk of long-term conditions.

Data also show significant improvements in quality of life and respiratory symptoms in patients with evidence of type 2 inflammation who were treated with dupilumab.

A one-of-its-kind assessment of 8 decades' worth of UK data show a lower respiratory tract infection by age 2 increases risk of premature adult death by 93%.

The new analysis on the screening tool in primary care patients with COPD highlights the need for further research to optimize CAPTURE's performance and impact on clinical outcomes.

Frailty is a serious issue in hospitalized patients and is associated with increased morbidity and mortality. However, a recent study suggests that the Hospital Frailty Risk Score (HFRS), may not be effective in identifying frailty in hospitalized COPD patients compared to the bedside Clinical Frailty Scale (CFS).

The analysis uses patient data from SPIROMICS, followed by an external validation with the results from COPDGene.

The medication was approved for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.

Neither intervention group demonstrated any significant improvements in intensity of chronic breathlessness after taking regular, low-dose, extended-release morphine.

These data support web-based self-management for individuals with COPD with an objective, clinically relevant, short-term increase in physical activity levels compared to usual care.

“From this study it makes sense that the (icenticaftor) 300mg dose has a benefit-risk profile to further study the clinical benefits,” Dr. Frits Franssen, lead investigator, said at ERS Congress 2022.

New phase 3 ENHANCE-2 data support a potential submission by Verona Pharma to the FDA.

Though current use rates have declined since 2017, investigators believe more young adults are transitioning from experimental to habitual use.

Early follow-up in patients with COPD led to lower rates of readmissions at 90 days, while patients with CHF saw lower 90-day mortality.

Dr. Trudzinski speaks of the importance of diagnosing sex-specific pulmonary and extra-pulmonary comorbidities in women with COPD, as well as the lack of research regarding COPD prevalence in women.

Dr. Richmond speaks to the newest pulmonology data from Vanderbilt University that was presented at ATS 2022.

Previously, the US Preventive Services Task Force reviewed screening evidence for COPD in 2016 and issued a D recommendation against screening in asymptomatic adults.

The 2022 State of the Air report from the American Lung Association highlights growing disparities in coastal-based ozone and particle pollution, amid wildfires and shifts in regulatory policies.

Overall tobacco use declined among adults since 2019—but many from varying sociodemographic backgrounds are still reporting high use.

The inhaler is approved for 2 strengths, 160/4.5 mcg/actuation and 80/4.5 mcg/actuation.

Dr. Shrine and colleagues conducted the largest genome-wide association study of coexisting asthma and COPD to date in a 2-stage design incorporating a total of 13 studies.

Take a Break was a 3-week interactive experience that involved motivational text messages, challenge quizzes, brief goal setting and more.

The discriminative accuracy of the 3 instruments were evaluated in low- and middle-income settings in Nepal, Peru, and Uganda, with further research needed to determine whether implementation is associated with improved clinical outcomes.

Dr. Castro talks of the available biologic therapies that can be used to treat asthma and other respiratory disorders.

Investigators found that exposure to surgical smoke and disinfectants over a long period of time led to increased risk of COPD in US female nurses.